Coherus Insists Demand Is ‘Pent Up’ For On-Body Pegfilgrastim Biosimilar

As Company Plots ‘Very Careful Review Over Time’ For Udenyca PFS

 
• By Dean Rudge
  
Amgen logo sign hanging on the office building in Rotkreuz, Switzerland
"Taking share from Onpro will be a source of growth" • Source: Alamy

More from Biosimilars

More from Products